Bruker Corporation · NASDAQ:BRKR

Bruker — 39th Annual J.P. Morgan Healthcare Conference (January 2021)

24 slides from Bruker's conference presentation, Jan 11, 2021

  1. Slide 1: Bruker 2021 and Beyond: Project Accelerate 2.0

    Bruker 2021 and Beyond: Project Accelerate 2.0 Expanded Bruker Strategy and TAM - Unbiased Proteomics and Multiomics - Spatial Biology and Single-Cell Multiomics - Microbiology and Molecular Diagnostics JP Morgan 2021 Healthcare Conference Frank H. Laukien, President & CEO January 11, 2021 © Bruker

  2. Slide 2: Bruker Corporation Safe Harbor Statement

    Bruker Corporation Safe Harbor Statement Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934,

  3. Slide 3: Bruker Preliminary FY 2021 Outlook

    Bruker Preliminary FY 2021 Outlook Strong YoY revenue growth, margin expansion and EPS growth expected in FY 2021 Preliminary Q4 2020 Revenue: Preliminary FY 2021 Year-over-year Outlook(1)(2): • We currently expect Q4 2020 revenue of $620 - $625 million, including ~4.5% FX tailwind. • Expect organic

  4. Slide 4: Introducing Project Accelerate 2.0

    Introducing Project Accelerate 2.0 High Value Expanded Strategy & Incremental TAMs: Innovative • Unbiased Proteomics & Multiomics: $5-6B TAM Differentiated • Spatial Biology & Single-Cell Multiomics: $3-5B TAM Life Science Tools & • Microbiology & Molecular Dx: ~$20B TAM Diagnostic Solutions TAM = t

  5. Slide 5: Bruker's Dual Strategy

    Bruker’s Dual Strategy: • Transforming our portfolio for Project Accelerate 2.0 & Operational Excellence attractive secular growth trends drive customer success and profitable growth • Driving key product innovation cycles • Six high-growth, high-margin Project Accelerate 2.0 initiatives Profitable

  6. Slide 6: Project Accelerate 2.0

    Project Accelerate 2.0 Faster growth from six expanded high-growth, high-margin initiatives Unbiased Unbiased 4D Proteomics & Proteomics & 4D Multiomics, Functional Multiomics Structural Biology Consumables, Software, Service & Aftermarket MS and NMR solutions for Biopharma & proteomics, multiomics,

  7. Slide 7: Project Accelerate 2.0: Expanded Strategic Scope and Incremental TAMs

    Project Accelerate 2.0 Expanded Strategic Scope and Incremental TAMs for Bruker Unbiased Proteomics Spatial Biology & Microbiology & & Multiomics(1) Single-Cell Multiomics(2) Molecular Dx(3) Bruker TAM: Overall TAM: $4B Bruker TAM: Overall TAM: $5-6B $2B $3-5B Bruker TAM: $1B Overall TAM: $20B (1)Pr

  8. Slide 8: Unbiased 4D Proteomics by TIMS/PASEF

    Unbiased 4D Proteomics by TIMS/PASEF timsTOF is unlocking the transformative Pioneering Unbiased 4D power of CCS-enabled, deep 4D proteomics: Proteomics for Large Cohort Validation Large-cohort plasma • Excellent speed and robustness for >50 runs/day proteomics, PTMs • CCS-enabled 4D TIMS/PASEF for

  9. Slide 9: Unbiased 4D Proteomics by TIMS/PASEF

    Unbiased 4D Proteomics by TIMS/PASEF • Novel MALDI-2 option for timsTOF fleXTM Recent timsTOF Innovations ✓ 10x-100x sensitivity for many small molecules and lipids ✓ increases applications range of MALDI based MS imaging • Revolutionary CCS-enabled 4D Proteomics workflows: ✓ dia-PASEF for high thro

  10. Slide 10: Functional Structural Biology by GHz-NMR

    Functional Structural Biology by GHz-NMR GHz NMR enables Discoveries in disease research, e.g., COVID-19, Unique capabilities Alzheimer’s, CVD and Cancer - dynamics, function & binding of globular proteins - intrinsically disordered proteins and protein regions • Example: Viral RNA replication in ho

  11. Slide 11: COVID Disease Research: Drug binding by High-Field NMR

    COVID Disease Research: Drug binding by High-Field NMR Phenomics Research by NMR & Mass Spec Investigating Structures, Dynamics, Function and Collaboration with ANPC, Murdoch University to support Binding of SARS-CoV-2 Viral RNA and Proteins COVID-19 pheno-convesion and ‘long COVID’ research • Inter

  12. Slide 12: Spatial Biology & Single-Cell Multiomics

    Spatial Biology & Single-Cell Multiomics Canopy quantitative, high-resolution spatial biology Bruker ChipCytometry™: & targeted single-cell multiomics research now Quantitative Spatial Biology & Single-Cell Targeted Proteomics single-cell resolution now • High-plex imaging for quantitative spatial t

  13. Slide 13: Spatial Biology & Single-Cell Multiomics

    Spatial Biology & Single-Cell Multiomics Single Cell & Sub-Cellular Vutara™ VXL Best-in-Class Super-Resolution Targeted Spatial Genomics, Biological Workstation for Spatial Biology Transcriptomics and Proteomics oligoFISSEQ – interphase cell and metaphase spread • Multiscale widefield & super-resolu

  14. Slide 14: Microbiology & Molecular Diagnostics

    Microbiology & Molecular Diagnostics Expanding Infectious Disease Strategy and TAM Existing Dx Solutions New Assays & Platforms Fast MBT ID Growth MBT Product • MALDI Biotyper (MBT) installed base ~4,300 systems Development • Applied proteomics • Rapid adoption of 3rd generation MALDI Biotyper® siri

  15. Slide 15: Microbiology & Molecular Diagnostics

    Microbiology & Molecular Diagnostics Expanding & ramping our SARS-CoV-2 test portfolio(1) SARS-CoV-2 Testing in Europe • Bruker-Hain products for SARS-CoV-2(1): ✓ Automated sample prep systems ✓ Nucleic acid (NA) extraction kits MariPOC® system ✓ FluoroType® SARS-CoV-2 two-gene PCR with rule- out of

  16. Slide 16: MBT Sepsityper Kit US IVD December 2020 FDA Clearance

    Microbiology & Molecular Diagnostics MBT Sepsityper Kit US IVD® December 2020 FDA Clearance Fast Identification From Positive Blood Cultures Sepsis • When every hour counts Direct ID from positive blood culture (PBC) • ID possible in 15-20 minutes after PBC alert • Efficient and faster results to tr

  17. Slide 17: MBT Sepsityper Kit US IVD: Early Adopter Feedback

    Microbiology & Molecular Diagnostics FDA Clearance MBT Sepsityper Kit US IVD®: Early Adopter Feedback CE-IVD Mark •“…The MBT Sepsityper Kit US IVD will be •“Rapid (MBT) Sepsityper identification •“The MBT Sepsityper data has allowed us the next step for a lot of clinical has become instrumental in t

  18. Slide 18: Questions & Answers – Project Accelerate 2.0

    Questions & Answers – Project Accelerate 2.0 Expanded Bruker Strategy and TAM - Unbiased Proteomics and Multiomics - Spatial Biology and Single-Cell Multiomics - Microbiology and Molecular Diagnostics © Bruker Corporation Innovation with Integrity

  19. Slide 19: Appendix

    Appendix © Bruker Corporation Innovation with Integrity

  20. Slide 20: Growth, Profitability & Margin Expansion

    Growth, Profitability & Margin Expansion 2016-2019: Track Record of Improving Financial Performance(1) Revenue Growth Non-GAAP Operating Profit Margin Non-GAAP EPS (OPM) $2.07B $1.96B $1.57 $1.9B 17.6% $1.8B 16.8% 15.9% 15.7% $1.40 $1.6B 15.0% $1.30 $1.19 $1.21 2016A 2017A 2018A 2019A LTM 2016A 2017

  21. Slide 21: Reconciliation of GAAP to Non-GAAP Financial Measures

    Bruker Corporation Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) Three Months Nine Months Last Twelve Ended Ended Months Ended (in millions, except per share amounts) Twelve Months Ended December 31, December 31, September 30, September 30, (1) 2016 2017 (1) 2018 2019 2019 2020 2

  22. Slide 22: Reconciliation of GAAP to Non-GAAP Financial Measures

    Bruker Corporation Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) Three Months Nine Months Last Twelve Ended Ended Months Ended (in millions, except per share amounts) Twelve Months Ended December 31, December 31, September 30, September 30, (1) 2016 2017 (1) 2018 2019 2019 2020 2

  23. Slide 23: Reconciliation of GAAP to Non-GAAP Financial Measures

    Bruker Corporation Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) Three Months Nine Months Last Twelve Ended Ended Months Ended (in millions, except per share amounts) Twelve Months Ended December 31, December 31, September 30, September 30, (1) 2016 2017 (1) 2018 2019 2019 2020 2

  24. Slide 24: Reconciliation of GAAP to Non-GAAP Financial Measures

    Bruker Corporation Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) Three Months Nine Months Last Twelve Ended Ended Months Ended (in millions, except per share amounts) Twelve Months Ended December 31, December 31, September 30, September 30, (1) 2016 2017 (1) 2018 2019 2019 2020 2

Bruker — 39th Annual J.P. Morgan Healthcare Conference (January 2021) on 6ix